



Europass Curriculum Vitae

Insert photograph. (JPG format)

Personal information

First name(s) / Surname(s)

Isabella / Screpanti

Address(es)

Department of Molecular Medicine, Sapienza University of Rome. Viale Regina Elena 291, 00161 Rome. Italy

Telephone(s)

+39 06 49255140

Mobile:

Fax(es)

+39 06 49255671

E-mail

isabella.screpanti@uniroma1.it

Nationality

Italian

Date of birth

Gender

Occupational field

SSD MED/04

Work experience

Dates

2015-present Director of the PhD program in Molecular Medicine, Sapienza University of Rome
 2009-2014 Member of the Faculty of the PhD Program in Molecular Medicine, Sapienza University of Rome
 2008-2012 Member of the Sapienza University Working Group on the Academic Cooperation in Mediterranean Area
 2004-2012 Member of the International Relationship Committee of the Sapienza University of Rome. Rome, Italy
 2000-2015 Member of the Research Committee of the Sapienza University of Rome, Rome, Italy
 1999-present Full Professor, General Pathology, Faculty of Medicine and Surgery, Sapienza University of Rome, Rome, Italy
 1995-2008 Member of the Faculty of the PhD program in Immunological Sciences, Sapienza University of Rome
 1993-1999 Associate Professor, General Pathology, Faculty of Medicine and Surgery, Sapienza University of Rome, Rome, Italy
 1990-1993 Medical Assistant of Biotechnology Section of National Institute for Cancer Research (IST, Genoa), Italy
 1984-1989 Associate Investigator, Department of Experimental Medicine and Pathology, Sapienza University of Rome
 1985-1986 Visiting scientist, Laboratory of Experimental Immunology, FCRF, National Cancer Institute, Frederick, MD, USA

Occupation or position held

Full Professor of General Pathology, Faculty of Pharmacy and Medicine, Sapienza University of Rome.

Main activities and responsibilities

Professor; Director of the Molecular Pathology laboratory of Molecular Medicine Department

Name and address of employer

Sapienza University of Rome

Sector

Medical education

Education and training

Dates

1980-1984 Postdoctoral Fellow, Collège de France, C.N.R.S., Foundation for Hormone Research, Paris, France
 1979-1980 Postdoctoral fellow, Hopital Necker-Enfants Malades, Université Paris VI. Paris, France
 1977-1980 Postgraduate Specialization, Pediatrics, Catholic University of Rome. Rome, Italy.
 1971-1977 M.D. Degree, Medicine and Surgery School, Catholic University of Rome. Rome, Italy.

Personal skills and competences

Mother tongue(s)

Italian

Other language(s)

Self-assessment

European level (*)

French

Understanding		Speaking		Writing	
Listening	Reading	Spoken interaction	Spoken production		
C2	C2	C2	C2		

English	C2	C2	C1	C1
---------	----	----	----	----

(*) [Common European Framework of Reference for Languages](#)

Additional information

Prof. Screpanti has been Member of Committee for evaluation of "Tenure and Promotion" in USA Universities (Tuft University, MA; New York University, NYC; Miami University, FL; University of Massachusetts, Amherst, MA)
 She is referee for International Journals (Blood, EMBO J., J. Immunology, Immunity, Leukemia, PNAS, Experimental Cell Research, etc...) and Reviewer of Grant proposals for several International Agencies (HFSP, Association for International Cancer Research, Wellcome Trust, The French National Cancer Research Department, Fondation Recherche Medicale, Agence Nationale Recherche, Dutch Cancer Society, FWO-Belgium)

Awarded grants

In the last ten years Prof. Screpanti has been funded, as principal investigator (PI) or National scientific coordinator, from several National Agencies, both public (Ministry of Health; Ministry of the University (PRIN and FIRB projects); Sapienza University) and private (Associazione Italiana per la Ricerca sul Cancro, AIRC; Institut Pasteur-Fondazione Cenci-Bolognetti).

FP6: 2004-2008 Prof Screpanti has been the Italian partner of the Integrated Project EUROTHYMAIDE (contract LSHB-CT-2003-503410), funded with 12,000,000.00 Euros

FP7: 2009-2012 Prof. Screpanti has been the coordinator of NotchIT a Initial Training Network (FP7-PEOPLE-2007-1-1-ITN) (contract PITN-GA-2008-215761), funded with 3,500,000.00 Euro

Main research fields:

1. Analysis of cellular and molecular mechanisms involved in T cell and thymocyte differentiation
2. Development of in vitro thymocyte differentiation models
3. Generation and phenotypic and functional characterization of transgenic animals, as models of neoplastic diseases
4. Notch receptor triggered signal transduction
5. Identification of new molecular markers of lymphoid leukemias

Receiving

Annexes

List any items attached.

30 selected publications (years 2002-2017), out of 159 total publications (total citations: 6.300)

1. Bellavia D., Campese A.F., Checquolo S., Balestri A., Biondi A., Cazzaniga G., Lendahl U., Fehling H.J., Hayday A.C., Frati L., von Boehmer H., Gulino A., **Screpanti I.**, Combined expression of pTa and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. *Proc Natl Acad Sci U S A*. 99(6):3788-3793, 2002
2. **Screpanti I.**, Bellavia D., Campese A.F., Frati L., Gulino A. Notch, a unifying target in T cell acute lymphoblastic leukemia? *Trends Molecular Medicine* 9:30-35, 2003.
3. Bellavia D., Campese A.F., Vacca A., Gulino A., **Screpanti I.** Notch3, another Notch in T cell development and leukemogenesis. *Seminars Immunology* 15:107-12, 2003.
4. Pediconi N, Ianari A, Costanzo A, Belloni L, Gallo R, Cimino L, Porcellini A, Screpanti I, Balsano C, Alesse E, Gulino A*, Levrero M*. (*corresponding authors) Differential regulation of E2F1 apoptotic target genes in response to DNA damage. *Nature Cell Biology*. 5:552-558, 2003.
5. Anastasi E., Campese AF., Bellavia D., Bulotta A., Balestri A., Pascucci M., Checquolo S., Gradini R., Lendahl U., Frati L., Gulino A., Di Mario U., Screpanti I., Expression of Activated Notch3 In Transgenic Mice Enhances Generation of T Regulatory Cells and Protects Against Experimental Autoimmune Diabetes. *Journal Immunology* 171:4504-4511, 2003.
6. Talora C., Campese AF., Bellavia D., Pascucci M., Checquolo C., Gropioni M., von Boehmer H., Gulino A., Screpanti I. PreTCR-triggered ERK signaling-dependent downregulation of E2A activity in Notch3-induced T cell lymphoma. *EMBO Reports* 4(11):1067-71, 2003
7. Tacconelli A., Farina AR., Cappabianca L., DeSantis G., Tessitore A., Vetuschi A., Sferra R., Rucci N., Argenti B., **Screpanti I.**; Gulino A., Mackay AR. TrkA Alternative Splicing: a Regulated Tumor Promoting Switch in Human Neuroblastoma. *Cancer Cell* 6:347-360, 2004
8. Felli MP, Vacca A, Calce A, Bellavia D, Campese AF, Grillo R, Di Giovine M, Checquolo S, Talora C, Palermo R, Di Mario G, Frati L, Gulino A, **Screpanti I.** PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia. *Oncogene* 24:992-1000, 2005.
9. Mandal M, Borowski C, Palomero T, Ferrando AA, Oberdoerffer P, Meng F, Ruiz-Vela A, Ciofani M, Zuniga-Pflucker JC, **Screpanti I**, Look AT, Korsmeyer SJ, Rajewsky K, von Boehmer H, Aifantis I. The BCL2A1 gene as a pre-T cell receptor-induced regulator of thymocyte survival. *Journal of Experimental Medicine* 201:603-614, 2005
10. Talora C, Cialfi S, Oliviero C, Palermo R, Pascucci M, Frati L, Vacca A, Gulino A, **Screpanti I.** Cross-talk among Notch3, pre-TCR and Tal-1 in T-cell development and leukemogenesis. *Blood* 107(8):3313-20, 2006.
11. Vacca A, Felli MP, Palermo R, Di Mario G, Calce A, Di Giovine M, Frati L, Gulino A, **Screpanti I.** Notch3 and pre-TCR interaction unveils distinct NF- κ B pathways in T cell development and leukemogenesis. *EMBO Journal* 25:1000-8., 2006.
12. A.F. Campese, A.I. Garbe, F. Zhang, F. Grassi, I. **Screpanti** and H. von Boehmer. Notch1-dependent lymphomagenesis is assisted by but does not essentially require pre-TCR signaling. *Blood* 2006; 108:305-10
13. Bellavia D, Mecarozzi M, Campese AF, Grazioli P, Talora C, Frati L, Gulino A, **Screpanti I.** Notch3 and the Notch3-upregulated RNA-binding protein HuD regulate Ikaros alternative splicing. *EMBO Journal* 26(6):1670-1680, 2007
14. Bellavia D, Checquolo S, Campese AF, Felli MP, Gulino A, **Screpanti I.** Notch3: from subtle structural differences to functional diversity. *Oncogene* 27(38):5092-5098, 2008.
15. Giannini E, Lattanzi R, Nicotra A, Campese AF, Grazioli P, **Screpanti I**, Balboni G, Salvadori S, Sacerdote P, Negri L. The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. *Proc Natl Acad Sci U S A*. 106(34):14646-51, 2009
16. Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K, Bartoli A, Coaccioli S, **Screpanti I**, Marconi P. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. *Blood*. 113(4):856-65, 2009
17. Ianari A, Natale T, Calo E, Ferretti E, Alesse E, **Screpanti I**, Haigis K, Gulino A, Lees JA. Proapoptotic function of the retino blastoma tumor suppressor protein. *Cancer Cell*. 15(3):184-194, 2009.
18. Checquolo S, Palermo R, Cialfi S, Ferrara G, Oliviero C, Talora C, Bellavia D, Giovenco A, Grazioli P, Frati L, Gulino A, **Screpanti I.** Differential subcellular localization regulates c-Cbl E3 ligase activity upon Notch3 protein in T-cell leukemia. *Oncogene*. 2010 Mar 11;29(10):1463-74.
19. Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P, Pietrosanti L, De Smaele E, Ferretti E, Miele E, Pelloni M, De Simone G, Pedone EM, Gallinari P, Giorgi A, Steinkühler C, Vitagliano L, Pedone C, Schinin ME, **Screpanti I**, Gulino A. Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. *Nature Cell Biology*. 2010 Feb;12(2):132-42.
20. Martinelli S, De Luca A, Stellacci E, Rossi C, Checquolo S, Lepri F, Caputo V, Silvano M, Buscherini F, Consoli F, Ferrara G, Digilio MC, Cavaliere ML, van Hagen JM, Zampino G, van der Burgt I, Ferrero GB, Mazzanti L, **Screpanti I**, Yntema HG, Nillesen WM, Savarirayan R, Zenker M, Dallapiccola B, Gelb BD, Tartaglia M. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. *Am J Hum Genet*. 2010 Aug 13;87(2):250-7.
21. Rosati E, Sabatini R, Rampino G, De Falco F, Di Ianni M, Falzetti F, Fettucciari K, Bartoli A, **Screpanti I**, Marconi P. Novel targets for endoplasmic reticulum stress-induced apoptosis in B-CLL. *Blood*. 2010 Oct 14;116(15):2713-23.
22. Barbarulo A, Grazioli P, Campese AF, Bellavia D, Di Mario G, Pelullo M, Ciuffetta A, Colantoni S, Vacca A, Frati L, Gulino A, Felli MP, **Screpanti I.** Notch3 and canonical NF- κ B signaling pathways cooperatively regulate Foxp3 transcription. *J Immunol*. 2011 Jun 1;186(11):6199-206.
23. Cialfi S, Palermo R, Manca S, Checquolo S, Bellavia D, Pelullo M, Quaranta R, Dominici C, Gulino A, **Screpanti I**, Talora C. Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression. *Leukemia*. 2012 Jul 13. doi:10.1038/leu.2012.192. [Epub ahead of print]
24. Palermo R, Checquolo S, Giovenco A, Grazioli P, Kumar V, Campese AF, Giorgi A, Napolitano M, Canettieri G, Ferrara G, Schininà ME, Maroder M, Frati L, Gulino A, Vacca A, Screpanti I. Acetylation controls Notch3 stability and function in T-cell leukemia. *Oncogene*. 2012 Aug 16;31(33):3807-17.
25. Jin S, Mutvei AP, Chivukula IV, Andersson ER, Ramsköld D, Sandberg R, Lee KL, Kronqvist P, Mamaeva V, Ostling P, Mpindi JP, Kallioniemi O, **Screpanti I**, Poellinger L, Sahlgren C, Lendahl U. Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKK α /IKK β . *Oncogene*. 2013 Oct 10;32(41):4892-902. doi: 10.1038/onc.2012.517. Epub 2012 Nov 26.
26. Kumar V, Palermo R, Talora C, Campese AF, Checquolo S, Bellavia D, Tottone L, Testa G, Miele E, Indraccolo S, Amadori A, Ferretti E, Gulino A, Vacca A, **Screpanti I.** Notch and NF- κ B signaling pathways regulate miR-223/FBXW7 axis in T cell acute lymphoblastic leukemia. *Leukemia*. 2014 Apr 14. doi: 10.1038/leu.2014.133. [Epub ahead of print]
27. De Falco F, Sabatini R, Falzetti F, Di Ianni M, Sportoletti P, Baldoni S, Del Papa B, **Screpanti I**, Marconi P, Rosati E. Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation. *Leukemia*. 2014 Nov 26. doi: 10.1038/leu.2014.329. [Epub ahead of print]
28. Vargas Romero P, Cialfi S, Palermo R, De Blasio C, Checquolo S, Bellavia D, Chiaretti S, Foà R, Amadori A, Gulino A, Zardo G, Talora C, **Screpanti I.** The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBP α . *Leukemia*. 2015 Dec;29(12):2442-5. doi: 10.1038/leu.2015.117. Epub 2015 May 18.
29. Franciosa G, Diluvio G, Del Gaudio F, Giuli MV, Palermo R, Grazioli P, Campese AF, Talora C, Bellavia D, D'Amati G, Besharat ZM, Nicoletti C, Siebel CW, Choy L, Rustighi A, Del Sal G, **Screpanti I.** Chequolo S. Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression. *Oncogene*. 2016 Feb 15. doi: 10.1038/onc.2016.5.
30. Palchetti S, Pozzi D, Marchini C, Amici A, Andreani C, Bartolacci C, Digiacomo L, Gambini V, Cardarelli F, Di Rienzo C, Peruzzi G, Amenitsch H, Palermo R, **Screpanti I**, Caracciolo G. Manipulation of lipoplex concentration at the cell surface boosts transfection efficiency in hard-to-transfect cells. *Nanomedicine*. 2017 Feb;13(2):681-691. doi: 10.1016/j.nano.2016.08.019.

Roma, 24 March 2017

SIGNED ISABELLA SCREPANTI